Neal Goodwin Email and Phone Number

Structural Biology Designed Therapeutics| Oncology Targeted Therapeutics

Targeted therapeutics for neurodegenerative disease.

◆ Developed advanced AAV vector and non-viral nanoparticle gene delivery enabling technologies.◆ Implemented synthetic biology laboratory for cell line engineering and AAV vector design.◆ Established AAV downstream processing, nanoparticle formulation, molecular biology, genomics, and bioreactor platforms.◆ Delivered technology in-licensing deal for directed evolution-derived AAV vectors.◆ Instituted Scientific Affairs program for client engagement, program awareness, licensing technology assessment, and developing academic and client partnerships.◆ Part of C-Team that contributed to successful IPO (NASDAQ: TKNO).

◆ Developed RAL GTPase inhibitor portfolio for KRAS mutant cancers and tumor initiation and metastasis inhibition.◆ Earned State of Colorado Advanced Industries Early-Stage Capital and Retention Award.◆ Delivered technology in-licensing deal for RAL GTPase KRAS precision medicine assets.

◆ Played a key role in improving corporate value leading to successful stock uplisting to NASDAQ (CSBR).◆ Facilitated pharmaceutical industry B2B alliances and corporate development of strategic partnerships securing significant non-dilutive agreements from top-tier pharmaceutical/biotech companies.◆ Raised strategic client base by more than 60% in the US, Asia, and Europe.◆ Launched a differentiated technology platform for extensive business growth within the hematology-oncology and immuno-oncology sectors.

◆ Founded and managed CRO cancer services business unit. ◆ Instituted 27-member NCI-Cancer Center PDX consortium for PDX pharmacology services platform aiding the pharmaceutical industry.◆ Managed humanized hematology-oncology and immuno-oncology platforms.◆ Received two internal institutional Employee of Year Awards, two external peer-granted research honors, and external program recognition through PBS Newshour and USA Today media coverage. ◆ Improved JAX organization development efforts.

◆ Co-founded publicly-traded oncology-focused pharmaceutical enterprise, including designing differentiated strategy and technologies contributing to $13M+ in venture, grant, and angel investment through initial IND and $158M IPO (NASDAQ: SRRA; Acquired by GSK for $1.9B).◆ Advanced DNA inhibition clinical therapeutics for hematology-oncology.◆ Co-invented nanoparticle drug delivery and manufacturing technologies.◆ Served as principal investigator on $5.2M in awarded grants.

◆ Responsible for mouse modeling approximately one-fourth of the discovery portfolio including arthritis and inflammation, oncology, and metabolic disease therapeutic areas.◆ Managed high-speed functional genomics mutagenesis projects, and mouse-based ES cell technologies.